1748-1749 / 2437
Presented by:
Nader Sanai, MD
AZD1775 plasma exposure increased with the increase of dose
2 to 24 h after 400mg dose, unbound (pharmacologically-active) drug
concentrations in tumor ranged from
18 – 315 ng/g
, with mean concentration
(
85 ng/g
) >
in vitro
IC
50
(42 ng/mL)
for inhibition of cellular Wee1 activity
1
10
100
0 4 8 12 16 20 24 28
Unbound AZD1775 Plasma Conc.
(ng/mL)
Sampling Time (h)
Dose, 100 mg
Dose, 200 mg
Dose, 400 mg
1
10
100
1000
0 4 8 12 16 20 24 28
Unbound AZD1775 Tumor Conc.
(ng/g)
Sampling Time (h)
Dose, 100 mg
Dose, 200 mg
Dose, 400 mg
AZD1775 Pharmacokinetics in GBM
in vitro
IC
50
(42 ng/mL) for
inhibition of cellular Wee1
Blood
Tumor